Bretylium Tosylate CAS: 61-75-6
MF: C18H24BrNO3S
MW: 414.36
An inhibitor of AChE.

Bretylium Tosylate (CAS 61-75-6)

Bretylium Tosylate | CAS 61-75-6 is rated 5.0 out of 5 by 1.
  • y_2021, m_7, d_31, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.18
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_360745, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 110ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: Bretylol; Bretylate; Ornid
Application: Bretylium Tosylate is an inhibitor of AChE
CAS Number: 61-75-6
Molecular Weight: 414.36
Molecular Formula: C18H24BrNO3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

Bretylium Tosylate is an inhibitor of AChE. Bretylium tosylate has a biphasic response, initially inducing norepinephrine release followed by sympathetic ganglionic blockade. Bretylium tosylate is a class III antiarrhythmic agent and a competitive inhibitor of acetylcholinesterase

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in water (50 mg/ml), ethanol, methanol, and chloroform. Insoluble in ether, ethyl acetate, and hexane.
Storage :
Store at room temperature
Melting Point :
97.8° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
BO9450000
PubChem CID :
Merck Index :
14: 1371
MDL Number :
MFCD00038731
EC Number :
200-516-8
SMILES :
CC[N+](C)(C)CC1=CC=CC=C1Br.CC1=CC=C(C=C1)S(=O)(=O)[O-]

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 100ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from McGinn et al McGinn et al. (PubMed ID 24687586) found that Bretylium Tosylate inhibited noradrenergic vasoconstriction and increased postexercise cutaneous vascular conductance. -SCBT Publication Review
Date published: 2015-05-14
  • y_2021, m_7, d_31, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.18
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_360745, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 8ms
  • REVIEWS, PRODUCT